TABLE 3.

Overview of TEAEs reported by participants

TEAE, n (%)	Trazpiroben 25 mg (n = 12)	Trazpiroben 25 mg + rifampin 600 mg (n = 12)	Overall (n = 12)
Number of participants with TEAEs	6 (50)	2 (17)	6 (50)
Gastrointestinal disorders	1 (8)	0 (0)	1 (8)
Abdominal pain, upper	1 (8)	0 (0)	1 (8)
Nervous system disorders	3 (25)	1 (8)	3 (25)
Headache	2 (17)	1 (8)	2 (17)
Sensory disturbance	1 (8)	0 (0)	1 (8)
Respiratory, thoracic, and mediastinal disorders	1 (8)	1 (8)	2 (17)
Cough	0 (0)	1 (8)	1 (8)
Nasal congestion	0 (0)	1 (8)	1 (8)
Sinus congestion	1 (8)	0 (0)	1 (8)
Sneezing	1 (8)	0 (0)	1 (8)
Skin and subcutaneous tissue disorders	1 (8)	0 (0)	1 (8)
Dermatitis contact	1 (8)	0 (0)	1 (8)

Note: Adverse events are classified according to the Medical Dictionary for Regulatory activities (MedDRA) version 22.1. If a participant had two or more clinical adverse events within a category, the participant is counted only once within the category.

Abbreviation: TEAE, treatment‐emergency adverse event.